KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin (2018 - 2025)

Historic Net Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 0.6%.

  • Castle Biosciences' Net Margin fell 32500.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.55%, marking a year-over-year decrease of 55000.0%. This contributed to the annual value of 5.49% for FY2024, which is 316400.0% up from last year.
  • Per Castle Biosciences' latest filing, its Net Margin stood at 0.6% for Q3 2025, which was down 32500.0% from 5.29% recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Net Margin peaked at 11.11% during Q4 2024, and registered a low of 91.7% during Q1 2022.
  • Its 5-year average for Net Margin is 24.44%, with a median of 18.76% in 2021.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -729400bps in 2022, then skyrocketed by 660000bps in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Net Margin stood at 25.68% in 2021, then crashed by -109bps to 53.78% in 2022, then soared by 93bps to 3.9% in 2023, then skyrocketed by 385bps to 11.11% in 2024, then plummeted by -105bps to 0.6% in 2025.
  • Its last three reported values are 0.6% in Q3 2025, 5.29% for Q2 2025, and 29.38% during Q1 2025.